Stryker (NYSE:SYK) updated its second quarter earnings guidance on Tuesday. The company provided earnings per share guidance of $1.90-1.95 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.96. Stryker also updated its FY 2019 guidance to $8.05-8.20 EPS.

Several brokerages recently commented on SYK. Canaccord Genuity raised their target price on Stryker from $185.00 to $190.00 and gave the company a buy rating in a report on Wednesday, January 30th. Zacks Investment Research upgraded Stryker from a hold rating to a buy rating and set a $199.00 target price on the stock in a report on Monday, February 4th. Morgan Stanley dropped their target price on Stryker from $212.00 to $197.00 and set an overweight rating on the stock in a report on Wednesday, January 2nd. Royal Bank of Canada raised their target price on Stryker from $184.00 to $204.00 and gave the company an outperform rating in a report on Monday, March 11th. Finally, Cantor Fitzgerald reiterated a neutral rating on shares of Stryker in a report on Friday, January 18th. Nine equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $192.13.

SYK stock traded up $4.80 during midday trading on Tuesday, hitting $186.96. 2,754,379 shares of the company’s stock were exchanged, compared to its average volume of 1,434,516. The company has a quick ratio of 1.41, a current ratio of 2.02 and a debt-to-equity ratio of 0.72. Stryker has a 12-month low of $144.75 and a 12-month high of $199.85. The company has a market capitalization of $67.26 billion, a PE ratio of 25.58, a P/E/G ratio of 2.19 and a beta of 0.88.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, April 23rd. The medical technology company reported $1.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.84 by $0.04. Stryker had a return on equity of 27.60% and a net margin of 26.12%. The company had revenue of $3.52 billion for the quarter, compared to the consensus estimate of $3.51 billion. During the same period in the previous year, the business earned $1.68 EPS. Stryker’s revenue for the quarter was up 8.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Stryker will post 8.13 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a dividend of $0.52 per share. The ex-dividend date is Thursday, March 28th. This represents a $2.08 annualized dividend and a yield of 1.11%. Stryker’s dividend payout ratio is presently 28.45%.

In other news, VP M Kathryn Fink sold 180 shares of the business’s stock in a transaction that occurred on Monday, February 4th. The stock was sold at an average price of $176.77, for a total value of $31,818.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Kevin Lobo sold 41,750 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $194.11, for a total value of $8,104,092.50. The disclosure for this sale can be found here. Insiders have sold a total of 130,455 shares of company stock worth $24,723,292 over the last 90 days. 7.20% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Story: What is a Leveraged Buyout (LBO)?

Earnings History and Estimates for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with's FREE daily email newsletter.